董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Julie Krop | 女 | Director | 54 | 未披露 | 未持股 | 2021-05-05 |
| Nancy Lurker | 女 | Director | 63 | 11.85万美元 | 未持股 | 2021-05-05 |
| James S. Scibetta | 男 | Director | 56 | 13.15万美元 | 未持股 | 2021-05-05 |
| Keith J. Kendall | 男 | Chief Executive Officer, President and Director | 63 | 129.04万美元 | 未持股 | 2021-05-05 |
| John Cochran | 男 | Vice Chairman of the Board | 55 | 11.85万美元 | 未持股 | 2021-05-05 |
| Santo Costa | 男 | Chairman of the Board | 75 | 14.85万美元 | 未持股 | 2021-05-05 |
| Marco Taglietti | 男 | Director | 61 | 未披露 | 未持股 | 2021-05-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Keith J. Kendall | 男 | Chief Executive Officer, President and Director | 63 | 129.04万美元 | 未持股 | 2021-05-05 |
| Daniel Barber | 男 | Senior Vice President - Chief Operating Officer | 45 | 84.01万美元 | 未持股 | 2021-05-05 |
| Peter Boyd | 男 | Senior Vice President - Business Process and Information Technology | 55 | 未披露 | 未持股 | 2021-05-05 |
| Ken Marshall | 男 | Senior Vice President - Chief Commercial Officer | 60 | 未披露 | 未持股 | 2021-05-05 |
| A. Mark Schobel | 男 | Chief Innovation and Technology Officer | 65 | 79.52万美元 | 未持股 | 2021-05-05 |
| Theresa Wood | 女 | Senior Vice President - Human Resources and Organizational Development | 58 | 未披露 | 未持股 | 2021-05-05 |
| Lori J. Braender | -- | Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary | 65 | 未披露 | 未持股 | 2021-05-05 |
| Gary H. Slatko | -- | Senior Vice President - Chief Medical Officer | 64 | 未披露 | 未持股 | 2021-05-05 |
| A. Ernest Toth, Jr. | -- | Interim Chief Financial Officer | 62 | 未披露 | 未持股 | 2021-05-05 |
董事简历
中英对照 | 中文 | 英文- Julie Krop
-
Julie Krop，2015年6月加入担任临床开发和管理事务高级副总裁和首席医疗官。加入公司之前，2012年2月-2015年5月，Krop博士在上市生物科技公司Vertex Pharmaceuticals, Inc.中担任越来越重的职务，最近她担任临床开发副总裁。在Vertex之前，2006年10月-2011年12月，Krop博士在Stryker Corporation担任多个职位。2003年6月-2006年10月，Krop博士在生物科技公司 Peptimmune Inc.中担任临床研发副总裁；2001年2月-2003年6月在上市生物制药公司Millennium Pharmaceuticals, Inc.中担任临床开发主管，之后该公司被Takeda Pharmaceutical Company Limited；1999年7月-2001年2月担任上市生物制药公司Pfizer, Inc.担任副总监。Krop博士持有Brown University学士学位， the Warren Alpert Medical School of Brown University医学学位。她在 Georgetown University Hospital 医学系完成住院医生实习期，并且是the Johns Hopkins University School of Medicine内分泌系奖学金。此外，Krop博士曾是一名罗伯特·伍德·约翰逊基金会临床学者。
Julie Krop has served as a member of our Board since February 2021. Since April 2020 Dr. Krop has served as Chief Medical Officer of Freeline Therapeutics Holdings plc Nasdaq: FRLN, a clinical stage gene therapy company, and has more than 20 years of drug development experience across multiple therapeutic areas including orphan drug indications. Dr. Krop served from 2015 to April 2020 as the Chief Medical Officer and Executive Vice President, Development of AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG), where she oversaw clinical development, medical affairs, program management, and pharmacovigilance and regulatory functions. Prior to joining AMAG, Dr. Krop held leadership positions at Vertex Pharmaceuticals, Inc. from 2012 to 2015 including Internal Medicine Development Lead and Vice President, Clinical Development, and had leadership positions at Pfizer, Inc. from 1999 to 2001 at Millennium Pharmaceuticals, Inc. from 2001 to 2003 at Peptimmune from 2003 to 2006 and at Stryker Regenerative Medicine from 2006 to 2012. Dr. Krop is board certified in Internal Medicine and completed a Robert Wood Johnson Foundation Clinical Scholar Fellowship as well as an Endocrinology fellowship at the Johns Hopkins University School of Medicine. Dr. Krop received both a B.A. and an M.D. from Brown University. - Julie Krop，2015年6月加入担任临床开发和管理事务高级副总裁和首席医疗官。加入公司之前，2012年2月-2015年5月，Krop博士在上市生物科技公司Vertex Pharmaceuticals, Inc.中担任越来越重的职务，最近她担任临床开发副总裁。在Vertex之前，2006年10月-2011年12月，Krop博士在Stryker Corporation担任多个职位。2003年6月-2006年10月，Krop博士在生物科技公司 Peptimmune Inc.中担任临床研发副总裁；2001年2月-2003年6月在上市生物制药公司Millennium Pharmaceuticals, Inc.中担任临床开发主管，之后该公司被Takeda Pharmaceutical Company Limited；1999年7月-2001年2月担任上市生物制药公司Pfizer, Inc.担任副总监。Krop博士持有Brown University学士学位， the Warren Alpert Medical School of Brown University医学学位。她在 Georgetown University Hospital 医学系完成住院医生实习期，并且是the Johns Hopkins University School of Medicine内分泌系奖学金。此外，Krop博士曾是一名罗伯特·伍德·约翰逊基金会临床学者。
- Julie Krop has served as a member of our Board since February 2021. Since April 2020 Dr. Krop has served as Chief Medical Officer of Freeline Therapeutics Holdings plc Nasdaq: FRLN, a clinical stage gene therapy company, and has more than 20 years of drug development experience across multiple therapeutic areas including orphan drug indications. Dr. Krop served from 2015 to April 2020 as the Chief Medical Officer and Executive Vice President, Development of AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG), where she oversaw clinical development, medical affairs, program management, and pharmacovigilance and regulatory functions. Prior to joining AMAG, Dr. Krop held leadership positions at Vertex Pharmaceuticals, Inc. from 2012 to 2015 including Internal Medicine Development Lead and Vice President, Clinical Development, and had leadership positions at Pfizer, Inc. from 1999 to 2001 at Millennium Pharmaceuticals, Inc. from 2001 to 2003 at Peptimmune from 2003 to 2006 and at Stryker Regenerative Medicine from 2006 to 2012. Dr. Krop is board certified in Internal Medicine and completed a Robert Wood Johnson Foundation Clinical Scholar Fellowship as well as an Endocrinology fellowship at the Johns Hopkins University School of Medicine. Dr. Krop received both a B.A. and an M.D. from Brown University.
- Nancy Lurker
-
Nancy Lurker，2016年9月以来，她一直担任Eyepoint Pharmaceuticals Inc.的总裁和首席执行官。2008年至2015年，她曾担任PDI, Inc（纳斯达克上市的医疗商业化公司，现称为Interpace Diagnostics Group, Inc）的总裁兼首席执行官兼董事。2006年至2007年，她曾担任Novartis Pharmaceuticals Corporation（Novartis AG的美国子公司）的高级副总裁兼首席营销官。2003年至2006年，她曾担任ImpactRx, Inc.（私人医疗信息公司）的总裁兼首席执行官。1998年至2003年，她曾担任Pharmacia Corporation Pharmacia（目前从属于Pfizer, Inc）的集团副总裁，负责全球初级保健产品，以及一般疗法副总裁。她也曾担任Pharmacia公司的美国执行管理委员会成员。此前，她曾任职Bristol-Myers Squibb Company，担任销售代表，晋升为全球心血管特许经营管理的高级主管。她担任X4 Pharmaceuticals, Inc（私人公司）的董事会主席、the Cancer Treatment Centers of America（私人公司）的董事会成员。她此前曾担任私人公司（Auxilium Pharmaceuticals, Inc.）的董事会成员（2011年至2015年）、Mallinckrodt Pharmaceuticals, plc（2013年至2016年）的董事会成员，也担任PDI, Inc的董事（2008年至2015年）。她获得西雅图太平洋大学（Seattle Pacific University）的生物学学士学位，以及the University of Evansville的工商管理硕士学位。
Nancy Lurker has served as a member of Board of Directors of Eyepoint Pharmaceuticals Inc. since April 2018. Ms. Lurker has served as President, Chief Executive Officer and Director of Eyepoint Pharmaceuticals, Inc. Nasdaq: EYPT, a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, since September 2016. Prior to assuming her position with Eyepoint Pharmaceuticals, Ms. Lurker was a freelance consultant from December 2015 to September 2016. From 2008 to December 2015 Ms. Lurker served as Chief Executive Officer and a director of PDI, Inc., a Nasdaq-listed healthcare commercialization company now named Interpace Bioscience, Inc. (Nasdaq: IDXG). From 2006 to 2007 Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG (NYSE: NVS). In addition, Ms. Lurker also served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company. Ms. Lurker currently serves on the board of directors of the Cancer Treatment Centers of America, a privately held company. Ms. Lurker previously served as a member of the boards of directors of publicly held Auxilium Pharmaceuticals, Inc. from 2011 to 2015 Mallinckrodt Pharmaceuticals, plc from 2013 to 2016 Elan Corporation, plc from 2005 to 2006 and ConjuChem Biotechnologies from 2004 to 2006. Ms. Lurker currently serves on the Advisory Board of Novo Holdings A/S, Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S. Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. - Nancy Lurker，2016年9月以来，她一直担任Eyepoint Pharmaceuticals Inc.的总裁和首席执行官。2008年至2015年，她曾担任PDI, Inc（纳斯达克上市的医疗商业化公司，现称为Interpace Diagnostics Group, Inc）的总裁兼首席执行官兼董事。2006年至2007年，她曾担任Novartis Pharmaceuticals Corporation（Novartis AG的美国子公司）的高级副总裁兼首席营销官。2003年至2006年，她曾担任ImpactRx, Inc.（私人医疗信息公司）的总裁兼首席执行官。1998年至2003年，她曾担任Pharmacia Corporation Pharmacia（目前从属于Pfizer, Inc）的集团副总裁，负责全球初级保健产品，以及一般疗法副总裁。她也曾担任Pharmacia公司的美国执行管理委员会成员。此前，她曾任职Bristol-Myers Squibb Company，担任销售代表，晋升为全球心血管特许经营管理的高级主管。她担任X4 Pharmaceuticals, Inc（私人公司）的董事会主席、the Cancer Treatment Centers of America（私人公司）的董事会成员。她此前曾担任私人公司（Auxilium Pharmaceuticals, Inc.）的董事会成员（2011年至2015年）、Mallinckrodt Pharmaceuticals, plc（2013年至2016年）的董事会成员，也担任PDI, Inc的董事（2008年至2015年）。她获得西雅图太平洋大学（Seattle Pacific University）的生物学学士学位，以及the University of Evansville的工商管理硕士学位。
- Nancy Lurker has served as a member of Board of Directors of Eyepoint Pharmaceuticals Inc. since April 2018. Ms. Lurker has served as President, Chief Executive Officer and Director of Eyepoint Pharmaceuticals, Inc. Nasdaq: EYPT, a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, since September 2016. Prior to assuming her position with Eyepoint Pharmaceuticals, Ms. Lurker was a freelance consultant from December 2015 to September 2016. From 2008 to December 2015 Ms. Lurker served as Chief Executive Officer and a director of PDI, Inc., a Nasdaq-listed healthcare commercialization company now named Interpace Bioscience, Inc. (Nasdaq: IDXG). From 2006 to 2007 Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG (NYSE: NVS). In addition, Ms. Lurker also served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company. Ms. Lurker currently serves on the board of directors of the Cancer Treatment Centers of America, a privately held company. Ms. Lurker previously served as a member of the boards of directors of publicly held Auxilium Pharmaceuticals, Inc. from 2011 to 2015 Mallinckrodt Pharmaceuticals, plc from 2013 to 2016 Elan Corporation, plc from 2005 to 2006 and ConjuChem Biotechnologies from 2004 to 2006. Ms. Lurker currently serves on the Advisory Board of Novo Holdings A/S, Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S. Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.
- James S. Scibetta
-
JamesS.Scibetta自2013年11月以来一直担任我们的董事会成员。他目前是Maverick Therapeutics（一个发展阶段的免疫肿瘤学公司）的首席执行官。任职Maverick公司之前，他曾担任Pacira Pharmaceuticals公司的总裁兼首席财务官。Nasdaq:PCRX，一家专业制药公司，他自2015年10月起担任该职位。在此之前，Scibetta先生自2008年起担任Pacira的首席财务官。在2008年8月加入Pacira之前，在2007年BioEnvision Inc.（纳斯达克市场代码:BIVN）被Genzyme收购之后，他担任健赞公司的顾问。从2006年到2007年，Scibetta先生担任BioEnvision的首席财务官。从2001年到2006年，他担任Merrimack Pharmaceuticals Inc.（纳斯达克市场代码:MACK）的执行Vice President和首席财务官。Scibetta先生此前曾在以下生命科学公司的董事会任职:Nephros Inc.（纳斯达克市场代码:NEPH）、Merrimack Pharmaceuticals和LabopharmInc.在获得执行管理经验之前，Scibetta先生在投资银行工作了十多年，负责为广泛的公共和私营梦百合和生命科学公司采购和执行交易。Scibetta先生在维克森林大学（Wake Forest University）获得物理学理学士学位，并在密歇根大学（University of Michigan）获得工商管理硕士学位。
James S. Scibetta,has served as a member of Matinas Biopharma Holdings, Inc. Board since November 2013. Mr. Scibetta is currently the Chief Executive Officer of ImmuneID, Inc., a privately held company developing therapies targeting autoimmune disease. Prior to ImmuneID, Mr. Scibetta was Chief Executive Officer of Maverick Therapeutics, a development stage immune-oncology company, from 2017 until 2021 when it was acquired by Takeda Pharmaceutical Company Limited. Prior to Maverick, he was President from 2015 to 2017 and Chief Financial Officer from 2008 to 2015 of Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), a specialty pharmaceutical company. Prior to joining Pacira in August 2008, he served as a consultant to Genzyme Corporation following the sale of Bioenvision Inc. (NASDAQ: BIVN) to Genzyme in 2007. From 2006 to 2007 Mr. Scibetta was CFO of Bioenvision. From 2001 to 2006, he was Executive Vice President and Chief Financial Officer of Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Mr. Scibetta has previously served on the board of directors at the following life sciences companies: Aquestive Therapeutics (NASDAQ: AQST), Nephros Inc. (NASDAQ: NEPH), Merrimack Pharmaceuticals and Labopharm Inc. (NASDAQ: DDSS). Prior to his executive management experience, Mr. Scibetta spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad range of public and private healthcare and life sciences companies. Mr. Scibetta received his Bachelor of Science in Physics from Wake Forest University and an MBA from the University of Michigan. - JamesS.Scibetta自2013年11月以来一直担任我们的董事会成员。他目前是Maverick Therapeutics（一个发展阶段的免疫肿瘤学公司）的首席执行官。任职Maverick公司之前，他曾担任Pacira Pharmaceuticals公司的总裁兼首席财务官。Nasdaq:PCRX，一家专业制药公司，他自2015年10月起担任该职位。在此之前，Scibetta先生自2008年起担任Pacira的首席财务官。在2008年8月加入Pacira之前，在2007年BioEnvision Inc.（纳斯达克市场代码:BIVN）被Genzyme收购之后，他担任健赞公司的顾问。从2006年到2007年，Scibetta先生担任BioEnvision的首席财务官。从2001年到2006年，他担任Merrimack Pharmaceuticals Inc.（纳斯达克市场代码:MACK）的执行Vice President和首席财务官。Scibetta先生此前曾在以下生命科学公司的董事会任职:Nephros Inc.（纳斯达克市场代码:NEPH）、Merrimack Pharmaceuticals和LabopharmInc.在获得执行管理经验之前，Scibetta先生在投资银行工作了十多年，负责为广泛的公共和私营梦百合和生命科学公司采购和执行交易。Scibetta先生在维克森林大学（Wake Forest University）获得物理学理学士学位，并在密歇根大学（University of Michigan）获得工商管理硕士学位。
- James S. Scibetta,has served as a member of Matinas Biopharma Holdings, Inc. Board since November 2013. Mr. Scibetta is currently the Chief Executive Officer of ImmuneID, Inc., a privately held company developing therapies targeting autoimmune disease. Prior to ImmuneID, Mr. Scibetta was Chief Executive Officer of Maverick Therapeutics, a development stage immune-oncology company, from 2017 until 2021 when it was acquired by Takeda Pharmaceutical Company Limited. Prior to Maverick, he was President from 2015 to 2017 and Chief Financial Officer from 2008 to 2015 of Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), a specialty pharmaceutical company. Prior to joining Pacira in August 2008, he served as a consultant to Genzyme Corporation following the sale of Bioenvision Inc. (NASDAQ: BIVN) to Genzyme in 2007. From 2006 to 2007 Mr. Scibetta was CFO of Bioenvision. From 2001 to 2006, he was Executive Vice President and Chief Financial Officer of Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Mr. Scibetta has previously served on the board of directors at the following life sciences companies: Aquestive Therapeutics (NASDAQ: AQST), Nephros Inc. (NASDAQ: NEPH), Merrimack Pharmaceuticals and Labopharm Inc. (NASDAQ: DDSS). Prior to his executive management experience, Mr. Scibetta spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad range of public and private healthcare and life sciences companies. Mr. Scibetta received his Bachelor of Science in Physics from Wake Forest University and an MBA from the University of Michigan.
- Keith J. Kendall
-
KeithJ.Kendall自2014年11月以来一直担任我们的总裁兼首席执行官，自2011年11月以来一直担任我们的总裁兼首席运营官，并自2014年11月以来一直担任我们的董事会成员。Kendall先生还从2006年开始担任我司执行Vice President和首席财务官。Kendall从2010年1月到2014年12月担任Midatech，Pharma plc（NASDAQ:MTP）董事。从1999年到2006年，肯德尔先生担任惠普金融服务公司（Hewlett Packard Financial Services）的美洲Vice President兼总经理。Kendall从1985年到1998年在AT&T Capital Corporation担任多个职位，包括AT&T Credit Corporation和NCR Credit Corporation总裁。Kendall先生拥有St.John&8217；s University的学士学位和Pace University的工商管理硕士学位。
Keith J. Kendall has served as our Chief Executive Officer and President and as a member of our Board since November 2014 after having served as our President and Chief Operating Officer from November 2011 to November 2014 and as our Executive Vice President and Chief Financial Officer from 2006 to 2011. From 1999 to 2006 Mr. Kendall served in various business leadership positions for Hewlett Packard Financial Services, most recently as Vice President and Managing Director of the Americas. From 1985 to 1998 Mr. Kendall held a number of positions with AT&T Capital Corporation, including President of AT&T Credit Corporation and NCR Credit Corporation. Mr. Kendall served on the board of directors of Midatech Pharma Plc Nasdaq: MTP from January 2010 to December 2014. Mr. Kendall holds a B.S. from St. John’s University and an M.B.A from Pace University. - KeithJ.Kendall自2014年11月以来一直担任我们的总裁兼首席执行官，自2011年11月以来一直担任我们的总裁兼首席运营官，并自2014年11月以来一直担任我们的董事会成员。Kendall先生还从2006年开始担任我司执行Vice President和首席财务官。Kendall从2010年1月到2014年12月担任Midatech，Pharma plc（NASDAQ:MTP）董事。从1999年到2006年，肯德尔先生担任惠普金融服务公司（Hewlett Packard Financial Services）的美洲Vice President兼总经理。Kendall从1985年到1998年在AT&T Capital Corporation担任多个职位，包括AT&T Credit Corporation和NCR Credit Corporation总裁。Kendall先生拥有St.John&8217；s University的学士学位和Pace University的工商管理硕士学位。
- Keith J. Kendall has served as our Chief Executive Officer and President and as a member of our Board since November 2014 after having served as our President and Chief Operating Officer from November 2011 to November 2014 and as our Executive Vice President and Chief Financial Officer from 2006 to 2011. From 1999 to 2006 Mr. Kendall served in various business leadership positions for Hewlett Packard Financial Services, most recently as Vice President and Managing Director of the Americas. From 1985 to 1998 Mr. Kendall held a number of positions with AT&T Capital Corporation, including President of AT&T Credit Corporation and NCR Credit Corporation. Mr. Kendall served on the board of directors of Midatech Pharma Plc Nasdaq: MTP from January 2010 to December 2014. Mr. Kendall holds a B.S. from St. John’s University and an M.B.A from Pace University.
- John Cochran
-
John Cochran自2004年1月以来一直担任我们的董事会成员。Cochran先生从1998年10月开始一直担任Bratton Capital Management L.P.的合伙人，并负责其私募股权投资。Cochran先生也是Crestline Management的合伙人兼首席运营官，该公司是一家以信贷为导向的另类资产管理平台。在加入Bratton Capital Management L.P.之前，Cochran先生在毕马威会计师事务所（KPMG）工作了10年，主要专注于审计和并购尽职调查。Cochran先生在德克萨斯基督教大学（Texas Christian University）获得会计学学士学位，也是一名有执照的注册会计师。
John Cochran has served as a member of our Board of Directors since January 2004 and was appointed to serve as Vice Chairman of the Board effective April 22 2020. Mr. Cochran has been a partner at Bratton Capital Management L.P. since October 1998 and is responsible for its private equity investments. Mr. Cochran is also a partner and Chief Operating Officer of Crestline Investors, an institutional alternative investment management firm. Prior to joining Bratton Capital Management L.P., Mr. Cochran spent 10 years with KPMG focused primarily on audit and merger and acquisition due diligence. Mr. Cochran received his B.A. in Accounting from Texas Christian University and is also a licensed certified public accountant. - John Cochran自2004年1月以来一直担任我们的董事会成员。Cochran先生从1998年10月开始一直担任Bratton Capital Management L.P.的合伙人，并负责其私募股权投资。Cochran先生也是Crestline Management的合伙人兼首席运营官，该公司是一家以信贷为导向的另类资产管理平台。在加入Bratton Capital Management L.P.之前，Cochran先生在毕马威会计师事务所（KPMG）工作了10年，主要专注于审计和并购尽职调查。Cochran先生在德克萨斯基督教大学（Texas Christian University）获得会计学学士学位，也是一名有执照的注册会计师。
- John Cochran has served as a member of our Board of Directors since January 2004 and was appointed to serve as Vice Chairman of the Board effective April 22 2020. Mr. Cochran has been a partner at Bratton Capital Management L.P. since October 1998 and is responsible for its private equity investments. Mr. Cochran is also a partner and Chief Operating Officer of Crestline Investors, an institutional alternative investment management firm. Prior to joining Bratton Capital Management L.P., Mr. Cochran spent 10 years with KPMG focused primarily on audit and merger and acquisition due diligence. Mr. Cochran received his B.A. in Accounting from Texas Christian University and is also a licensed certified public accountant.
- Santo Costa
-
Santo Costahas，2015年12月起，担任本公司董事。Costa先生自2007年以来一直担任北卡罗来纳州罗利市Smith，Anderson，Blount，Dorsett，Mitchell and Jernigan，L.L.P.律师事务所的法律顾问，专门为梦百合公司提供公司法服务。Costa先生曾在Cytokinetics Inc.的董事会任职。Nasdaq:CYTK，2010年10月起，担任Metabolon，Inc.的董事，2013年4月起。从1994年到2001年，他曾担任Quintiles Transnational Corporation的多种职务，包括副主席、总裁兼首席运营官。在加入昆泰公司之前，科斯塔先生在制药业工作了23年，最近的职务是担任葛兰素公司的总法律顾问和高级副总裁，管理人员。加入Glaxo公司之前，他曾担任Merrell Dow Pharmaceuticals公司的美国地区法律顾问，以及Norwich Eaton Pharmaceuticals公司的食品和药物法律顾问。Costa从2014年3月到2015年6月担任Alchemia Limited（一家私人生物制药公司）董事长。他也曾任职于Magor Corporation（原Biovest Corp.）的董事会。i，2010年3月至2013年3月。他也曾担任Labopharm公司的董事会主席（从2006年3月到2011年11月）、OSI Pharmaceuticals公司的董事（从2006年6月到2010年6月），也曾担任其它私人公司的董事。Costa先生在圣约翰大学（St.John&8217；s University）获得药学学士学位和法学博士学位。
Santo Costa has served as our Board Chairman since August 2018 and has served as a member of our Board of Directors since December 2015. Since 2007 Mr. Costa has served as Of Counsel to the law firm of Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. of Raleigh, North Carolina, specializing in corporate law for healthcare companies. Mr. Costa has served on the board of directors of Cytokinetics Inc. Nasdaq: CYTK since October 2010. From 1994 to 2001 he held various positions at Quintiles Transnational Corporation, including as Vice Chairman, President and Chief Operating Officer. Prior to joining Quintiles, Mr. Costa spent 23 years in the pharmaceutical industry, most recently as General Counsel and Senior Vice President, Administration with Glaxo Inc. Prior to joining Glaxo, he served as U.S. Area Counsel with Merrell Dow Pharmaceuticals and as Food & Drug Counsel with Norwich Eaton Pharmaceuticals, Inc. Mr. Costa served as chairman of the board of directors of Alchemia Limited (then traded on the ASX: ACL), a biopharmaceutical company, from March 2014 to June 2015 and on the board of directors of Metabolon, Inc., a private company, from April 2013 to May 2019. He also served on the board of directors of Magor Corporation, formerly Biovest Corp. I, from March 2010 until March 2013. He also served as chairman of the board of directors of LaboPharm, Inc. from March 2006 to November 2011 and a director of OSI Pharmaceuticals from June 2006 to June 2010 as well as serving as a director at other private companies. Mr. Costa earned both a B.S. in Pharmacy and a J.D. from St. John’s University. - Santo Costahas，2015年12月起，担任本公司董事。Costa先生自2007年以来一直担任北卡罗来纳州罗利市Smith，Anderson，Blount，Dorsett，Mitchell and Jernigan，L.L.P.律师事务所的法律顾问，专门为梦百合公司提供公司法服务。Costa先生曾在Cytokinetics Inc.的董事会任职。Nasdaq:CYTK，2010年10月起，担任Metabolon，Inc.的董事，2013年4月起。从1994年到2001年，他曾担任Quintiles Transnational Corporation的多种职务，包括副主席、总裁兼首席运营官。在加入昆泰公司之前，科斯塔先生在制药业工作了23年，最近的职务是担任葛兰素公司的总法律顾问和高级副总裁，管理人员。加入Glaxo公司之前，他曾担任Merrell Dow Pharmaceuticals公司的美国地区法律顾问，以及Norwich Eaton Pharmaceuticals公司的食品和药物法律顾问。Costa从2014年3月到2015年6月担任Alchemia Limited（一家私人生物制药公司）董事长。他也曾任职于Magor Corporation（原Biovest Corp.）的董事会。i，2010年3月至2013年3月。他也曾担任Labopharm公司的董事会主席（从2006年3月到2011年11月）、OSI Pharmaceuticals公司的董事（从2006年6月到2010年6月），也曾担任其它私人公司的董事。Costa先生在圣约翰大学（St.John&8217；s University）获得药学学士学位和法学博士学位。
- Santo Costa has served as our Board Chairman since August 2018 and has served as a member of our Board of Directors since December 2015. Since 2007 Mr. Costa has served as Of Counsel to the law firm of Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. of Raleigh, North Carolina, specializing in corporate law for healthcare companies. Mr. Costa has served on the board of directors of Cytokinetics Inc. Nasdaq: CYTK since October 2010. From 1994 to 2001 he held various positions at Quintiles Transnational Corporation, including as Vice Chairman, President and Chief Operating Officer. Prior to joining Quintiles, Mr. Costa spent 23 years in the pharmaceutical industry, most recently as General Counsel and Senior Vice President, Administration with Glaxo Inc. Prior to joining Glaxo, he served as U.S. Area Counsel with Merrell Dow Pharmaceuticals and as Food & Drug Counsel with Norwich Eaton Pharmaceuticals, Inc. Mr. Costa served as chairman of the board of directors of Alchemia Limited (then traded on the ASX: ACL), a biopharmaceutical company, from March 2014 to June 2015 and on the board of directors of Metabolon, Inc., a private company, from April 2013 to May 2019. He also served on the board of directors of Magor Corporation, formerly Biovest Corp. I, from March 2010 until March 2013. He also served as chairman of the board of directors of LaboPharm, Inc. from March 2006 to November 2011 and a director of OSI Pharmaceuticals from June 2006 to June 2010 as well as serving as a director at other private companies. Mr. Costa earned both a B.S. in Pharmacy and a J.D. from St. John’s University.
- Marco Taglietti
-
Marco Taglietti, M.D。 ，2010年12月31日开始，担任公司研究和开发高级副总裁，Forest Research Institute, Inc的总裁。此前，自2008年12月，他担任本公司研究和开发副总裁。2007年8月，他加入Forest，担任研究和开发执行副总裁，和全资子公司Forest Research Institute, Inc的首席医疗官。加入本公司前，他在Stiefel Laboratories工作了3年，担任高级副总裁和全球研究和开发部的负责人。在这之前，他在先灵葆雅工作了12年，担任愈益重要的职务，其中包括抗感染，癌症，中枢神经，内分泌与皮肤病的全球临床研究副总裁。
Marco Taglietti has served as a member of our Board since February 2021. Since 2015 Dr. Taglietti has been President, Chief Executive Officer and Director of Scynexis, Inc. Nasdaq: SCYZ, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistant infections. From 2007 to 2014 Dr. Taglietti served in senior leadership positions at Forest Laboratories, Inc., a publicly traded pharmaceutical company, including Executive Vice President, Research and Development, and Chief Medical Officer, and also served as President of Forest Research Institute, a division of Forest Laboratories. Prior to joining Forest Laboratories, Inc. in 2007 Dr. Taglietti held the position of Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc. for three years. He joined Stiefel Laboratories, Inc. after 12 years at Schering-Plough Corporation where he held positions of increasing responsibilities including as Vice President (Executive Level), Clinical Research for Anti-Infectives, CNS, Endocrinology and Dermatology. Dr. Taglietti began his career at Marion Merrell Dow Research Institute. Dr. Taglietti currently serves on the board of directors of BioNJ, Inc., a life science trade association, and was previously a director of Delcath System, Inc. and NephroGenex, Inc. He received his medical degree and board certifications from the University of Pavia in Italy. - Marco Taglietti, M.D。 ，2010年12月31日开始，担任公司研究和开发高级副总裁，Forest Research Institute, Inc的总裁。此前，自2008年12月，他担任本公司研究和开发副总裁。2007年8月，他加入Forest，担任研究和开发执行副总裁，和全资子公司Forest Research Institute, Inc的首席医疗官。加入本公司前，他在Stiefel Laboratories工作了3年，担任高级副总裁和全球研究和开发部的负责人。在这之前，他在先灵葆雅工作了12年，担任愈益重要的职务，其中包括抗感染，癌症，中枢神经，内分泌与皮肤病的全球临床研究副总裁。
- Marco Taglietti has served as a member of our Board since February 2021. Since 2015 Dr. Taglietti has been President, Chief Executive Officer and Director of Scynexis, Inc. Nasdaq: SCYZ, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistant infections. From 2007 to 2014 Dr. Taglietti served in senior leadership positions at Forest Laboratories, Inc., a publicly traded pharmaceutical company, including Executive Vice President, Research and Development, and Chief Medical Officer, and also served as President of Forest Research Institute, a division of Forest Laboratories. Prior to joining Forest Laboratories, Inc. in 2007 Dr. Taglietti held the position of Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc. for three years. He joined Stiefel Laboratories, Inc. after 12 years at Schering-Plough Corporation where he held positions of increasing responsibilities including as Vice President (Executive Level), Clinical Research for Anti-Infectives, CNS, Endocrinology and Dermatology. Dr. Taglietti began his career at Marion Merrell Dow Research Institute. Dr. Taglietti currently serves on the board of directors of BioNJ, Inc., a life science trade association, and was previously a director of Delcath System, Inc. and NephroGenex, Inc. He received his medical degree and board certifications from the University of Pavia in Italy.
高管简历
中英对照 | 中文 | 英文- Keith J. Kendall
KeithJ.Kendall自2014年11月以来一直担任我们的总裁兼首席执行官，自2011年11月以来一直担任我们的总裁兼首席运营官，并自2014年11月以来一直担任我们的董事会成员。Kendall先生还从2006年开始担任我司执行Vice President和首席财务官。Kendall从2010年1月到2014年12月担任Midatech，Pharma plc（NASDAQ:MTP）董事。从1999年到2006年，肯德尔先生担任惠普金融服务公司（Hewlett Packard Financial Services）的美洲Vice President兼总经理。Kendall从1985年到1998年在AT&T Capital Corporation担任多个职位，包括AT&T Credit Corporation和NCR Credit Corporation总裁。Kendall先生拥有St.John&8217；s University的学士学位和Pace University的工商管理硕士学位。
Keith J. Kendall has served as our Chief Executive Officer and President and as a member of our Board since November 2014 after having served as our President and Chief Operating Officer from November 2011 to November 2014 and as our Executive Vice President and Chief Financial Officer from 2006 to 2011. From 1999 to 2006 Mr. Kendall served in various business leadership positions for Hewlett Packard Financial Services, most recently as Vice President and Managing Director of the Americas. From 1985 to 1998 Mr. Kendall held a number of positions with AT&T Capital Corporation, including President of AT&T Credit Corporation and NCR Credit Corporation. Mr. Kendall served on the board of directors of Midatech Pharma Plc Nasdaq: MTP from January 2010 to December 2014. Mr. Kendall holds a B.S. from St. John’s University and an M.B.A from Pace University.- KeithJ.Kendall自2014年11月以来一直担任我们的总裁兼首席执行官，自2011年11月以来一直担任我们的总裁兼首席运营官，并自2014年11月以来一直担任我们的董事会成员。Kendall先生还从2006年开始担任我司执行Vice President和首席财务官。Kendall从2010年1月到2014年12月担任Midatech，Pharma plc（NASDAQ:MTP）董事。从1999年到2006年，肯德尔先生担任惠普金融服务公司（Hewlett Packard Financial Services）的美洲Vice President兼总经理。Kendall从1985年到1998年在AT&T Capital Corporation担任多个职位，包括AT&T Credit Corporation和NCR Credit Corporation总裁。Kendall先生拥有St.John&8217；s University的学士学位和Pace University的工商管理硕士学位。
- Keith J. Kendall has served as our Chief Executive Officer and President and as a member of our Board since November 2014 after having served as our President and Chief Operating Officer from November 2011 to November 2014 and as our Executive Vice President and Chief Financial Officer from 2006 to 2011. From 1999 to 2006 Mr. Kendall served in various business leadership positions for Hewlett Packard Financial Services, most recently as Vice President and Managing Director of the Americas. From 1985 to 1998 Mr. Kendall held a number of positions with AT&T Capital Corporation, including President of AT&T Credit Corporation and NCR Credit Corporation. Mr. Kendall served on the board of directors of Midatech Pharma Plc Nasdaq: MTP from January 2010 to December 2014. Mr. Kendall holds a B.S. from St. John’s University and an M.B.A from Pace University.
- Daniel Barber
Daniel Barber我们的高级副总裁-首席战略和发展官，于2007年7月加入我们的团队，并自2014年4月以来领导我们的战略和发展职能。加入我们的团队之前，Barber曾担任Quest Diagnostics公司的公司规划和国际部门的多种职务。2010年，Barber先生对我们的前两个FDA批准的产品的发布活动进行了执行监督。从2013年开始，Barber先生帮助领导我们努力开发专有资产的内部管道。自那时起，他对我们的管道和合作伙伴关系活动负有执行责任。Barber先生在纽约州立大学杰纳索分校（State University of New York at Geneseo）获得学士学位，并在塞顿霍尔大学（Seton Hall University）获得工商管理硕士学位。
Daniel Barber our Senior Vice President - Chief Strategy and Development Officer, joined our team in July 2007 and has led our Strategy and Development functions since April 2014. Prior to joining our team, Mr. Barber held various positions with Quest Diagnostics in its corporate planning and international divisions. In 2010 Mr. Barber had executive oversight of our launch activities for our first two FDA approved products. Beginning in 2013 Mr. Barber helped lead our effort to develop an internal pipeline of proprietary assets. Since that time, he has had executive responsibility for our pipeline and partnership activities. Mr. Barber received his BA degree from State University of New York at Geneseo and an MBA from Seton Hall University.- Daniel Barber我们的高级副总裁-首席战略和发展官，于2007年7月加入我们的团队，并自2014年4月以来领导我们的战略和发展职能。加入我们的团队之前，Barber曾担任Quest Diagnostics公司的公司规划和国际部门的多种职务。2010年，Barber先生对我们的前两个FDA批准的产品的发布活动进行了执行监督。从2013年开始，Barber先生帮助领导我们努力开发专有资产的内部管道。自那时起，他对我们的管道和合作伙伴关系活动负有执行责任。Barber先生在纽约州立大学杰纳索分校（State University of New York at Geneseo）获得学士学位，并在塞顿霍尔大学（Seton Hall University）获得工商管理硕士学位。
- Daniel Barber our Senior Vice President - Chief Strategy and Development Officer, joined our team in July 2007 and has led our Strategy and Development functions since April 2014. Prior to joining our team, Mr. Barber held various positions with Quest Diagnostics in its corporate planning and international divisions. In 2010 Mr. Barber had executive oversight of our launch activities for our first two FDA approved products. Beginning in 2013 Mr. Barber helped lead our effort to develop an internal pipeline of proprietary assets. Since that time, he has had executive responsibility for our pipeline and partnership activities. Mr. Barber received his BA degree from State University of New York at Geneseo and an MBA from Seton Hall University.
- Peter Boyd
Peter Boyd我们的高级副总裁-运营和价值交付，于2013年8月加入我们公司，并自2014年4月以来领导我们的运营和价值交付职能。在担任现职之前，Boyd先生是Aquestive的业务流程Vice President。在加入我们之前，Boyd先生曾担任惠普公司（Hewlett-Packard Company）的美洲和APJ地区运营高级总监。在惠普公司（Hewlett-Packard Company）的15年职业生涯中，Boyd先生在业务流程改进和运营方面担任过各种职务。Boyd先生在维滕贝格大学（Wittenberg University）获得历史学学士学位，并在塞顿霍尔大学（Seton Hall University）获得金融学工商管理硕士学位。Boyd先生还获得了New School University的管理和城市政策分析硕士学位。
Peter Boyd our Senior Vice President - Operations and Value Delivery, joined our company in August 2013 and has led our Operations and Value Delivery functions since April 2014. Prior to his current position, Mr. Boyd was our Vice President of Business Process at Aquestive. Prior to joining us, Mr. Boyd served as Senior Director of Operations for the Americas and APJ Regions, at Hewlett-Packard Company. Throughout his 15-year career at the Hewlett-Packard Company, Mr. Boyd held a variety of positons in business process improvement and in operations. Mr. Boyd received a BA in History from Wittenberg University and an MBA in Finance from Seton Hall University. Mr. Boyd also received an MS in Management and Urban Policy Analysis from the New School University.- Peter Boyd我们的高级副总裁-运营和价值交付，于2013年8月加入我们公司，并自2014年4月以来领导我们的运营和价值交付职能。在担任现职之前，Boyd先生是Aquestive的业务流程Vice President。在加入我们之前，Boyd先生曾担任惠普公司（Hewlett-Packard Company）的美洲和APJ地区运营高级总监。在惠普公司（Hewlett-Packard Company）的15年职业生涯中，Boyd先生在业务流程改进和运营方面担任过各种职务。Boyd先生在维滕贝格大学（Wittenberg University）获得历史学学士学位，并在塞顿霍尔大学（Seton Hall University）获得金融学工商管理硕士学位。Boyd先生还获得了New School University的管理和城市政策分析硕士学位。
- Peter Boyd our Senior Vice President - Operations and Value Delivery, joined our company in August 2013 and has led our Operations and Value Delivery functions since April 2014. Prior to his current position, Mr. Boyd was our Vice President of Business Process at Aquestive. Prior to joining us, Mr. Boyd served as Senior Director of Operations for the Americas and APJ Regions, at Hewlett-Packard Company. Throughout his 15-year career at the Hewlett-Packard Company, Mr. Boyd held a variety of positons in business process improvement and in operations. Mr. Boyd received a BA in History from Wittenberg University and an MBA in Finance from Seton Hall University. Mr. Boyd also received an MS in Management and Urban Policy Analysis from the New School University.
- Ken Marshall
Ken Marshall于2018年1月加入我们公司，担任我们的商业领袖。在此之前，Marshall先生担任Aerocrine Inc.的美国总裁兼全球首席营销官。在该职位上，他制定了全球营销策略，并领导了美国业务的各个方面。Marshall从2008年到2011年担任Ikaria，Inc.（一家专注于重症监护的药物和设备公司）销售与市场营销Vice President。Marshall先生还在GlaxoSmithKline工作了17年，担任过多个高级职位，包括神经科、泌尿科、生命周期和艾滋病毒业务部门的市场营销Vice President。Marshall先生在西卡罗莱纳大学（Western Carolina University）获得营销与经济学学士学位，并在休斯顿浸信会大学（Houston Baptist University）获得工商管理硕士学位。
Ken Marshall joined our company in January 2018 as our Commercial Leader. Prior to that, Mr. Marshall served as U.S. President and Global Chief Marketing Officer for Aerocrine Inc. In that role, he developed the global marketing strategy and led all aspects of the U.S. business. Between 2008 and 2011 Mr. Marshall served as Vice President of Sales and Marketing for Ikaria, Inc., a drug and device company focused on critical care. Mr. Marshall also spent 17 years with GlaxoSmithKline and held several senior positions including Vice President of Marketing for the Neurology, Urology, Lifecycle and HIV business units. Mr. Marshall received his BSBA in Marketing and Economics from Western Carolina University and MBA from Houston Baptist University.- Ken Marshall于2018年1月加入我们公司，担任我们的商业领袖。在此之前，Marshall先生担任Aerocrine Inc.的美国总裁兼全球首席营销官。在该职位上，他制定了全球营销策略，并领导了美国业务的各个方面。Marshall从2008年到2011年担任Ikaria，Inc.（一家专注于重症监护的药物和设备公司）销售与市场营销Vice President。Marshall先生还在GlaxoSmithKline工作了17年，担任过多个高级职位，包括神经科、泌尿科、生命周期和艾滋病毒业务部门的市场营销Vice President。Marshall先生在西卡罗莱纳大学（Western Carolina University）获得营销与经济学学士学位，并在休斯顿浸信会大学（Houston Baptist University）获得工商管理硕士学位。
- Ken Marshall joined our company in January 2018 as our Commercial Leader. Prior to that, Mr. Marshall served as U.S. President and Global Chief Marketing Officer for Aerocrine Inc. In that role, he developed the global marketing strategy and led all aspects of the U.S. business. Between 2008 and 2011 Mr. Marshall served as Vice President of Sales and Marketing for Ikaria, Inc., a drug and device company focused on critical care. Mr. Marshall also spent 17 years with GlaxoSmithKline and held several senior positions including Vice President of Marketing for the Neurology, Urology, Lifecycle and HIV business units. Mr. Marshall received his BSBA in Marketing and Economics from Western Carolina University and MBA from Houston Baptist University.
- A. Mark Schobel
A.Mark Schobel于2005年12月加入我们的团队，并自2015年11月起担任我们的首席创新和技术官。Schobel先生于2014年11月担任我们的首席执行官兼联席总裁，并于2005年11月至2018年担任我们的董事会成员。从2001年到2005年，他曾担任Novartis公司的消费者健康业务单元的新技术和产品创新全球主管，在那里他曾开创薄膜输送系统药物。任职Novartis公司之前，Schobel先生曾担任Reed&Carnrick Pharmaceuticals，Warner-Lambert and Pharmaceutical Formulations Inc.的多个综合管理职位。Schobel先生在费尔利·迪金森大学（Fairleigh Dickinson University）获得化学学士学位，并已获得21项专利，并在从薄膜药物输送到纳米颗粒输送系统等领域拥有多项正在申请的专利。
A. Mark Schobel joined our team in December 2005 and has served as our Chief Innovation and Technology Officer since November 2015. Mr. Schobel served as our Chief Executive Officer and Co-President through November 2014 and served as a member of our board of directors from November 2005 through 2018. From 2001 to 2005 he was the Global Head of New Technology and Product Innovation for the Consumer Health Business Unit at Novartis where he pioneered thin film delivery of systemic drugs. Prior to Novartis, Mr. Schobel held various general management positions with Reed & Carnrick Pharmaceuticals, Warner-Lambert and Pharmaceutical Formulations Inc. Mr. Schobel received his BS in Chemistry from Fairleigh Dickinson University and has been awarded 21 patents along with having multiple patents pending in fields ranging from film drug delivery to nanoparticle delivery systems.- A.Mark Schobel于2005年12月加入我们的团队，并自2015年11月起担任我们的首席创新和技术官。Schobel先生于2014年11月担任我们的首席执行官兼联席总裁，并于2005年11月至2018年担任我们的董事会成员。从2001年到2005年，他曾担任Novartis公司的消费者健康业务单元的新技术和产品创新全球主管，在那里他曾开创薄膜输送系统药物。任职Novartis公司之前，Schobel先生曾担任Reed&Carnrick Pharmaceuticals，Warner-Lambert and Pharmaceutical Formulations Inc.的多个综合管理职位。Schobel先生在费尔利·迪金森大学（Fairleigh Dickinson University）获得化学学士学位，并已获得21项专利，并在从薄膜药物输送到纳米颗粒输送系统等领域拥有多项正在申请的专利。
- A. Mark Schobel joined our team in December 2005 and has served as our Chief Innovation and Technology Officer since November 2015. Mr. Schobel served as our Chief Executive Officer and Co-President through November 2014 and served as a member of our board of directors from November 2005 through 2018. From 2001 to 2005 he was the Global Head of New Technology and Product Innovation for the Consumer Health Business Unit at Novartis where he pioneered thin film delivery of systemic drugs. Prior to Novartis, Mr. Schobel held various general management positions with Reed & Carnrick Pharmaceuticals, Warner-Lambert and Pharmaceutical Formulations Inc. Mr. Schobel received his BS in Chemistry from Fairleigh Dickinson University and has been awarded 21 patents along with having multiple patents pending in fields ranging from film drug delivery to nanoparticle delivery systems.
- Theresa Wood
Theresa Wood我们的高级副总裁---人力资源和组织发展，自2006年9月以来一直担任我们人力资源职能的负责人。加入我们的团队之前，Wood从1999年到2006年担任Hewlett Packard Financial Services Americas Division人力资源主管。从1995年到1998年，Wood女士为金融服务、梦百合和消费品市场的几家公司提供咨询服务。在此之前，Wood女士在Sea-Land Service Corp.工作了七年。Wood女士在基恩大学（Kean University）获得管理学和营销学学士学位。
Theresa Wood our Senior Vice President - Human Resources and Organizational Development, has served as the head of our human resources function since September 2006. Prior to joining our team, Ms. Wood was the Director, Human Resources, for the Hewlett Packard Financial Services Americas division from 1999 to 2006. From 1995 to 1998 Ms. Wood provided consulting services to several companies in the Financial Services, Healthcare and Consumer Goods market. Prior to that, Ms. Wood spent seven years with Sea-Land Service Corp. Ms. Wood received her BS in Management Science and Marketing from Kean University.- Theresa Wood我们的高级副总裁---人力资源和组织发展，自2006年9月以来一直担任我们人力资源职能的负责人。加入我们的团队之前，Wood从1999年到2006年担任Hewlett Packard Financial Services Americas Division人力资源主管。从1995年到1998年，Wood女士为金融服务、梦百合和消费品市场的几家公司提供咨询服务。在此之前，Wood女士在Sea-Land Service Corp.工作了七年。Wood女士在基恩大学（Kean University）获得管理学和营销学学士学位。
- Theresa Wood our Senior Vice President - Human Resources and Organizational Development, has served as the head of our human resources function since September 2006. Prior to joining our team, Ms. Wood was the Director, Human Resources, for the Hewlett Packard Financial Services Americas division from 1999 to 2006. From 1995 to 1998 Ms. Wood provided consulting services to several companies in the Financial Services, Healthcare and Consumer Goods market. Prior to that, Ms. Wood spent seven years with Sea-Land Service Corp. Ms. Wood received her BS in Management Science and Marketing from Kean University.
- Lori J. Braender
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Gary H. Slatko
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- A. Ernest Toth, Jr.
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介